Cardio Diagnostics director granted 2,854 stock options

Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 2,854 shares of common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 2,854 shares of common stock. The options have an exercise price of $2.19 per share and expire on June 30, 2036. This is a compensation-related award, not an open-market trade, and brings her directly held option awards to a total of 12,367 underlying shares.

Insider Trade Summary

Grant/Award: 2,854 shares

Grant/Award 1 txn

Insider Betts Wendy J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	2,854	$2.19	$6K

Holdings After Transaction: Stock Options (Right to Buy) — 12,367 contracts (Direct)

Key Figures

Options granted: 2,854 options Exercise price: $2.19 per share Expiration date: June 30, 2036 +1 more

4 metrics

Options granted 2,854 options Grant to director Wendy J. Betts on June 30, 2026

Exercise price $2.19 per share Exercise price of newly granted options

Expiration date June 30, 2036 Expiry of granted stock options

Total options after grant 12,367 options Total underlying shares following transaction

Key Terms

Stock Options (Right to Buy), grant/award acquisition, exercise price, expiration date

4 terms

Stock Options (Right to Buy) financial

"security_title: Stock Options (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 2.1900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-30T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cardio Diagnostics (CDIO) report for Wendy J. Betts?

Cardio Diagnostics reported that director Wendy J. Betts received a grant of 2,854 stock options. These derivative securities give her the right to buy an equal number of common shares under a compensation award, rather than through an open-market purchase or sale.

At what price were the new Cardio Diagnostics (CDIO) stock options granted to Wendy J. Betts?

The new stock options granted to Wendy J. Betts have an exercise price of $2.19 per share. This means she can purchase Cardio Diagnostics common stock at $2.19 for each option when exercising, subject to any applicable vesting and plan terms.

How many Cardio Diagnostics (CDIO) shares are covered by Wendy J. Betts’s stock options after this Form 4?

After this grant, Wendy J. Betts holds stock options covering 12,367 underlying shares. This total reflects her direct derivative holdings reported in the filing, including the newly awarded 2,854 options tied to Cardio Diagnostics common stock.

When do Wendy J. Betts’s newly granted Cardio Diagnostics (CDIO) stock options expire?

The newly granted stock options to Wendy J. Betts expire on June 30, 2036. She can choose to exercise them at the $2.19 per share exercise price any time allowed under the plan before that expiration date, subject to vesting conditions.

Was this Cardio Diagnostics (CDIO) Form 4 transaction an open-market buy or sell?

No, the Form 4 shows a grant or award acquisition of stock options, not an open-market trade. Wendy J. Betts received 2,854 options as compensation, so no common shares were bought or sold on the market in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/02/2026 - 12:27 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Betts Wendy J

(Last)

(First)

(Middle)

311 W. SUPERIOR ST., SUITE 444

C/O CARDIO DIAGNOSTICS HOLDINGS, INC.

(Street)

CHICAGO

ILLINOIS

60654

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$2.19	06/30/2026		A		2,854		06/30/2026	06/30/2036	Common Stock	2,854	$2.19	12,367	D

Explanation of Responses:

	/s/Elisa Luqman as attorney-in-fact for Wendy Betts	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR